Cwm, LLC Beam Therapeutics Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Cwm, LLC holds 1,488 shares of BEAM stock, worth $37,631. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,488

Previous 1,515 1.78%

Holding current value

$37,631

Previous $35,000 2.86%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$22.57 - $33.14 $609 - $894	-27 Reduced 1.78%	1,488 $36,000
Q2 2024 Jul 09, 2024	SELL	$21.22 - $32.66 $657 - $1,012	-31 Reduced 2.01%	1,515 $35,000
Q1 2024 Apr 05, 2024	SELL	$23.46 - $45.07 $4,809 - $9,239	-205 Reduced 11.71%	1,546 $51,000
Q4 2023 Feb 01, 2024	SELL	$17.69 - $30.76 $4,157 - $7,228	-235 Reduced 11.83%	1,751 $48,000
Q3 2023 Oct 11, 2023	SELL	$23.01 - $32.46 $585,742 - $826,301	-25,456 Reduced 92.76%	1,986 $48,000
Q2 2023 Aug 03, 2023	SELL	$29.32 - $35.99 $33,571 - $41,208	-1,145 Reduced 4.01%	27,442 $876,000
Q1 2023 Apr 28, 2023	SELL	$30.15 - $48.79 $39,225 - $63,475	-1,301 Reduced 4.35%	28,587 $875,000
Q4 2022 Feb 01, 2023	SELL	$36.73 - $51.6 $215,201 - $302,324	-5,859 Reduced 16.39%	29,888 $1.17 Million
Q3 2022 Oct 27, 2022	SELL	$39.79 - $70.31 $46,355 - $81,911	-1,165 Reduced 3.16%	35,747 $1.7 Million
Q2 2022 Jul 28, 2022	BUY	$29.86 - $62.36 $1.1 Million - $2.3 Million	36,894 Added 204966.67%	36,912 $1.43 Million
Q1 2022 Apr 21, 2022	BUY	$53.73 - $82.16 $967 - $1,478	18 New	18 $1,000

Others Institutions Holding BEAM

# of Institutions

236

Shares Held

75.2M

Call Options Held

438K

Put Options Held

232K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account